サマリー

アジア太平洋地域の線維性疾患治療市場は、2023年から2030年の予測期間に6.0%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションです：
アジア太平洋地域の線維性疾患治療市場、治療法別（投薬、臓器移植、酸素療法、その他）、用途別（特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他）、エンドユーザー（病院、専門診療所、学術・研究機関、その他）、流通チャネル（病院薬局、小売薬局、その他）、国（中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、台湾、アジア太平洋地域以外）産業動向と2030年までの予測

アジア太平洋地域の線維性疾患治療市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 線維性疾患の有病率の上昇
- 線維症治療における技術的進歩

市場のプレーヤー：

アジア太平洋地域の線維性疾患治療市場の主要な市場プレイヤーを以下に紹介します：
- ベーリンガーインゲルハイムインターナショナルGmbH
- アッヴィー社（AbbVie Inc.
- ブリストル・マイヤーズ スクイブ・カンパニー
- ギリアド・サイエンシズ社（Gilead Sciences, Inc.
- テバ・ファーマシューティカル・インダストリーズ社
- サンド・インターナショナル社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 ASIA-PACIFIC 99
15.1.1 JAPAN 106
15.1.2 CHINA 108
15.1.3 INDIA 110
15.1.4 SOUTH KOREA 112
15.1.5 AUSTRALIA 114
15.1.6 SINGAPORE 116
15.1.7 THAILAND 118
15.1.8 MALAYSIA 120
15.1.9 INDONESIA 122
15.1.10 PHILIPPINES 124
15.1.11 VIETNAM 126
15.1.12 TAIWAN 128
15.1.13 REST OF ASIA-PACIFIC 130
16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 131
16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 131
17 SWOT ANALYSIS 132
18 COMPANY PROFILE 133
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 133
18.1.1 COMPANY SNAPSHOT 133
18.1.2 REVENUE ANALYSIS 133
18.1.3 COMPANY SHARE ANALYSIS 134
18.1.4 PRODUCT PORTFOLIO 134
18.1.5 RECENT DEVELOPMENTS 134
18.2 GENENTECH, INC. 135
18.2.1 COMPANY SNAPSHOT 135
18.2.2 COMPANY SHARE ANALYSIS 135
18.2.3 PRODUCT PORTFOLIO 136
18.2.4 RECENT DEVELOPMENTS 136
18.3 SANDOZ INTERNATIONAL GMBH 137
18.3.1 COMPANY SNAPSHOT 137
18.3.2 COMPANY SHARE ANALYSIS 137
18.3.3 PRODUCT PORTFOLIO 138
18.3.4 RECENT DEVELOPMENTS 138
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 139
18.4.1 COMPANY SNAPSHOT 139
18.4.2 REVENUE ANALYSIS 139
18.4.3 COMPANY SHARE ANALYSIS 140
18.4.4 PRODUCT PORTFOLIO 140
18.4.5 RECENT DEVELOPMENTS 140
18.5 ACCORD HEALTHCARE U.S. 141
18.5.1 COMPANY SNAPSHOT 141
18.5.2 COMPANY SHARE ANALYSIS 141
18.5.3 PRODUCT PORTFOLIO 142
18.5.4 RECENT DEVELOPMENTS 142
18.6 ABBVIE INC. 143
18.6.1 COMPANY SNAPSHOT 143
18.6.2 REVENUE ANALYSIS 143
18.6.3 PRODUCT PORTFOLIO 144
18.6.4 RECENT DEVELOPMENTS 144
18.7 ALPINE IMMUNE SCIENCES 145
18.7.1 COMPANY SNAPSHOT 145
18.7.2 REVENUE ANALYSIS 145
18.7.3 PRODUCT PORTFOLIO 146
18.7.4 RECENT DEVELOPMENTS 146
18.8 BELLBROOK LABS 147
18.8.1 COMPANY SNAPSHOT 147
18.8.2 PRODUCT PORTFOLIO 147
18.8.3 RECENT DEVELOPMENTS 147
18.9 BIOMX 148
18.9.1 COMPANY SNAPSHOT 148
18.9.2 REVENUE ANALYSIS 148
18.9.3 PRODUCT PORTFOLIO 149
18.9.4 RECENT DEVELOPMENTS 149
18.10 BRISTOL-MYERS SQUIBB COMPANY 150
18.10.1 COMPANY SNAPSHOT 150
18.10.2 REVENUE ANALYSIS 150
18.10.3 PRODUCT PORTFOLIO 151
18.10.4 RECENT DEVELOPMENTS 151
18.11 CAMBER PHARMACEUTICALS, INC. 152
18.11.1 COMPANY SNAPSHOT 152
18.11.2 PRODUCT PORTFOLIO 152
18.11.3 RECENT DEVELOPMENTS 152
18.12 ENVEDA 153
18.12.1 COMPANY SNAPSHOT 153
18.12.2 PRODUCT PORTFOLIO 153
18.12.3 RECENT DEVELOPMENTS 153
18.13 GILEAD SCIENCES, INC. 154
18.13.1 COMPANY SNAPSHOT 154
18.13.2 REVENUE ANALYSIS 154
18.13.3 PRODUCT PORTFOLIO 155
18.13.4 RECENT DEVELOPMENTS 155
18.14 INTERCEPT PHARMACEUTICALS, INC. 156
18.14.1 COMPANY SNAPSHOT 156
18.14.2 REVENUE ANALYSIS 156
18.14.3 PRODUCT PORTFOLIO 157
18.14.4 RECENT DEVELOPMENTS 157
18.15 KITHER BIOTECH S.R.L. 158
18.15.1 COMPANY SNAPSHOT 158
18.15.2 PRODUCT PORTFOLIO 158
18.15.3 RECENT DEVELOPMENTS 158
18.16 PHARMAXIS LTD 159
18.16.1 COMPANY SNAPSHOT 159
18.16.2 REVENUE ANALYSIS 159
18.16.3 PRODUCT PORTFOLIO 160
18.16.4 RECENT DEVELOPMENTS 160
18.17 REDX PHARMA PLC. 161
18.17.1 COMPANY SNAPSHOT 161
18.17.2 REVENUE ANALYSIS 161
18.17.3 PRODUCT PORTFOLIO 162
18.17.4 RECENT DEVELOPMENTS 162
18.18 VERONA PHARMA PLC 163
18.18.1 COMPANY SNAPSHOT 163
18.18.2 REVENUE ANALYSIS 163
18.18.3 PRODUCT PORTFOLIO 164
18.18.4 RECENT DEVELOPMENTS 164
19 QUESTIONNAIRE 165
20 RELATED REPORTS 168

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 46
TABLE 2 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 58
TABLE 3 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 4 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 59
TABLE 5 ASIA PACIFIC ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 6 ASIA PACIFIC OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 7 ASIA PACIFIC OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 8 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 65
TABLE 9 ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 10 ASIA PACIFIC HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 11 ASIA PACIFIC RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 12 ASIA PACIFIC CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 13 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 73
TABLE 15 ASIA PACIFIC HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 16 ASIA PACIFIC SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 17 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 18 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 19 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 80
TABLE 20 ASIA PACIFIC HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 21 ASIA PACIFIC RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 22 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 23 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 88
TABLE 24 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 88
TABLE 25 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 89
TABLE 26 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 89
TABLE 27 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 89
TABLE 28 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 89
TABLE 29 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 90
TABLE 30 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 90
TABLE 31 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 91
TABLE 32 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 91
TABLE 33 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 91
TABLE 34 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 91
TABLE 35 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 92
TABLE 36 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 92
TABLE 37 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 92
TABLE 38 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 93
TABLE 39 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 93
TABLE 40 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 93
TABLE 41 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 93
TABLE 42 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 94
TABLE 43 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 94
TABLE 44 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 94
TABLE 45 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 95
TABLE 46 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 95
TABLE 47 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 95
TABLE 48 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 95
TABLE 49 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 96
TABLE 50 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 96
TABLE 51 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 96
TABLE 52 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 97
TABLE 53 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 97
TABLE 54 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 97
TABLE 55 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 97
TABLE 56 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 98
TABLE 57 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 98
TABLE 58 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 59 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 99
TABLE 60 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 99
TABLE 61 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 99
TABLE 62 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 99
TABLE 63 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 100
TABLE 64 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 100
TABLE 65 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 100
TABLE 66 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 101
TABLE 67 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 101
TABLE 68 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 101
TABLE 69 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 101
TABLE 70 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 102
TABLE 71 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 102
TABLE 72 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
TABLE 73 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 103
TABLE 74 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 103
TABLE 75 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 103
TABLE 76 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 103
TABLE 77 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 104
TABLE 78 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 104
TABLE 79 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 104
TABLE 80 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 105
TABLE 81 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 105
TABLE 82 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 105
TABLE 83 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 105
TABLE 84 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 106
TABLE 85 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 86 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 87 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 107
TABLE 88 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 107
TABLE 89 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 107
TABLE 90 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 107
TABLE 91 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 108
TABLE 92 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 108
TABLE 93 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 108
TABLE 94 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 109
TABLE 95 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 109
TABLE 96 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 109
TABLE 97 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 109
TABLE 98 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 110
TABLE 99 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
TABLE 100 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 110
TABLE 101 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 111
TABLE 102 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 111
TABLE 103 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 111
TABLE 104 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 111
TABLE 105 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 112
TABLE 106 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 107 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 108 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 113
TABLE 109 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 113
TABLE 110 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 113
TABLE 111 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 113
TABLE 112 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 114
TABLE 113 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 114 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 115 REST OF ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 115